nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilutamide—CYP2C8—Tazarotene—psoriasis	0.156	0.239	CbGbCtD
Nilutamide—CYP2C8—Cholecalciferol—psoriasis	0.0667	0.102	CbGbCtD
Nilutamide—CYP2C8—Mycophenolate mofetil—psoriasis	0.0579	0.0886	CbGbCtD
Nilutamide—CYP2C19—Cholecalciferol—psoriasis	0.056	0.0857	CbGbCtD
Nilutamide—CYP2C9—Cholecalciferol—psoriasis	0.0466	0.0713	CbGbCtD
Nilutamide—CYP2C8—Hydrocortisone—psoriasis	0.0464	0.0711	CbGbCtD
Nilutamide—CYP2C8—Cyclosporine—psoriasis	0.0439	0.0671	CbGbCtD
Nilutamide—CYP2C19—Prednisone—psoriasis	0.0388	0.0594	CbGbCtD
Nilutamide—CYP2C19—Cyclosporine—psoriasis	0.0368	0.0563	CbGbCtD
Nilutamide—CYP2C9—Cyclosporine—psoriasis	0.0306	0.0468	CbGbCtD
Nilutamide—CYP2C8—Dexamethasone—psoriasis	0.0289	0.0442	CbGbCtD
Nilutamide—CYP2C19—Dexamethasone—psoriasis	0.0242	0.0371	CbGbCtD
Nilutamide—CYP2C9—Dexamethasone—psoriasis	0.0201	0.0308	CbGbCtD
Nilutamide—POR—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.0069	0.16	CbGpPWpGaD
Nilutamide—CYP2C8—CYP2E1 reactions—CYP2S1—psoriasis	0.00286	0.0664	CbGpPWpGaD
Nilutamide—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.00255	0.0592	CbGpPWpGaD
Nilutamide—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.00233	0.054	CbGpPWpGaD
Nilutamide—CYP2C8—Xenobiotics—CYP2S1—psoriasis	0.00177	0.0411	CbGpPWpGaD
Nilutamide—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.00158	0.0367	CbGpPWpGaD
Nilutamide—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.00144	0.0335	CbGpPWpGaD
Nilutamide—AR—Coregulation of Androgen receptor activity—ZMIZ1—psoriasis	0.00118	0.0273	CbGpPWpGaD
Nilutamide—AR—Androgen receptor signaling pathway—ZMIZ1—psoriasis	0.00087	0.0202	CbGpPWpGaD
Nilutamide—AR—Regulation of Androgen receptor activity—REL—psoriasis	0.000861	0.02	CbGpPWpGaD
Nilutamide—AR—Regulation of Androgen receptor activity—CARM1—psoriasis	0.000848	0.0197	CbGpPWpGaD
Nilutamide—AR—Coregulation of Androgen receptor activity—CARM1—psoriasis	0.000758	0.0176	CbGpPWpGaD
Nilutamide—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000736	0.0171	CbGpPWpGaD
Nilutamide—CYP2C8—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000726	0.0169	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—RUNX3—psoriasis	0.000711	0.0165	CbGpPWpGaD
Nilutamide—AR—Nuclear Receptors—VDR—psoriasis	0.000661	0.0153	CbGpPWpGaD
Nilutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000657	0.0152	CbGpPWpGaD
Nilutamide—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000648	0.015	CbGpPWpGaD
Nilutamide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000599	0.0139	CbGpPWpGaD
Nilutamide—CYP2C8—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000597	0.0138	CbGpPWpGaD
Nilutamide—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000591	0.0137	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—ZMIZ1—psoriasis	0.00057	0.0132	CbGpPWpGaD
Nilutamide—AR—Androgen receptor signaling pathway—CARM1—psoriasis	0.00056	0.013	CbGpPWpGaD
Nilutamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000532	0.0124	CbGpPWpGaD
Nilutamide—AR—Nuclear Receptor transcription pathway—VDR—psoriasis	0.000522	0.0121	CbGpPWpGaD
Nilutamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000486	0.0113	CbGpPWpGaD
Nilutamide—AR—Nuclear Receptors—PPARG—psoriasis	0.000461	0.0107	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000421	0.00976	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.000396	0.00918	CbGpPWpGaD
Nilutamide—AR—Nuclear Receptor transcription pathway—PPARG—psoriasis	0.000364	0.00845	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—VDR—psoriasis	0.000361	0.00837	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—IL10—psoriasis	0.000351	0.00815	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—IL13—psoriasis	0.000332	0.00771	CbGpPWpGaD
Nilutamide—CYP2C8—Biological oxidations—CYP2S1—psoriasis	0.000317	0.00735	CbGpPWpGaD
Nilutamide—CYP2C8—Metapathway biotransformation—CYP2S1—psoriasis	0.000313	0.00725	CbGpPWpGaD
Nilutamide—AR—Notch-mediated HES/HEY network—CD4—psoriasis	0.000308	0.00715	CbGpPWpGaD
Nilutamide—AR—FOXA1 transcription factor network—JUN—psoriasis	0.000291	0.00675	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—CYP2S1—psoriasis	0.000283	0.00656	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	0.000279	0.00647	CbGpPWpGaD
Nilutamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000275	0.00638	CbGpPWpGaD
Nilutamide—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	0.000274	0.00636	CbGpPWpGaD
Nilutamide—Alopecia—Dexamethasone—psoriasis	0.000268	0.000881	CcSEcCtD
Nilutamide—Hyperhidrosis—Mycophenolate mofetil—psoriasis	0.000267	0.00088	CcSEcCtD
Nilutamide—Hypertension—Hydrocortisone—psoriasis	0.000266	0.000877	CcSEcCtD
Nilutamide—Vomiting—Hydroxyurea—psoriasis	0.000266	0.000876	CcSEcCtD
Nilutamide—Discomfort—Prednisolone—psoriasis	0.000266	0.000875	CcSEcCtD
Nilutamide—Rash—Hydroxyurea—psoriasis	0.000264	0.000868	CcSEcCtD
Nilutamide—Anorexia—Mycophenolate mofetil—psoriasis	0.000264	0.000868	CcSEcCtD
Nilutamide—Dermatitis—Hydroxyurea—psoriasis	0.000263	0.000868	CcSEcCtD
Nilutamide—Malaise—Triamcinolone—psoriasis	0.000262	0.000863	CcSEcCtD
Nilutamide—Headache—Hydroxyurea—psoriasis	0.000262	0.000863	CcSEcCtD
Nilutamide—Syncope—Triamcinolone—psoriasis	0.000261	0.000858	CcSEcCtD
Nilutamide—Discomfort—Hydrocortisone—psoriasis	0.00026	0.000855	CcSEcCtD
Nilutamide—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000258	0.00599	CbGpPWpGaD
Nilutamide—Oedema—Prednisolone—psoriasis	0.000258	0.000849	CcSEcCtD
Nilutamide—Insomnia—Cyclosporine—psoriasis	0.000256	0.000844	CcSEcCtD
Nilutamide—Upper respiratory tract infection—Methotrexate—psoriasis	0.000256	0.000843	CcSEcCtD
Nilutamide—Loss of consciousness—Triamcinolone—psoriasis	0.000255	0.000841	CcSEcCtD
Nilutamide—Paraesthesia—Cyclosporine—psoriasis	0.000254	0.000838	CcSEcCtD
Nilutamide—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.000254	0.0059	CbGpPWpGaD
Nilutamide—Shock—Prednisolone—psoriasis	0.000254	0.000836	CcSEcCtD
Nilutamide—Erectile dysfunction—Methotrexate—psoriasis	0.000254	0.000835	CcSEcCtD
Nilutamide—Cough—Triamcinolone—psoriasis	0.000254	0.000835	CcSEcCtD
Nilutamide—Dyspnoea—Cyclosporine—psoriasis	0.000253	0.000832	CcSEcCtD
Nilutamide—Oedema—Hydrocortisone—psoriasis	0.000252	0.000829	CcSEcCtD
Nilutamide—Asthenia—Mycophenolic acid—psoriasis	0.000251	0.000828	CcSEcCtD
Nilutamide—Hypertension—Triamcinolone—psoriasis	0.000251	0.000826	CcSEcCtD
Nilutamide—AR—Regulation of Androgen receptor activity—JUN—psoriasis	0.00025	0.00581	CbGpPWpGaD
Nilutamide—Insomnia—Mycophenolate mofetil—psoriasis	0.00025	0.000823	CcSEcCtD
Nilutamide—Dyspepsia—Cyclosporine—psoriasis	0.000249	0.000822	CcSEcCtD
Nilutamide—Hyperhidrosis—Prednisolone—psoriasis	0.000249	0.000821	CcSEcCtD
Nilutamide—Nausea—Hydroxyurea—psoriasis	0.000248	0.000818	CcSEcCtD
Nilutamide—Paraesthesia—Mycophenolate mofetil—psoriasis	0.000248	0.000817	CcSEcCtD
Nilutamide—Pruritus—Mycophenolic acid—psoriasis	0.000248	0.000816	CcSEcCtD
Nilutamide—Shock—Hydrocortisone—psoriasis	0.000248	0.000816	CcSEcCtD
Nilutamide—Pneumonia—Methotrexate—psoriasis	0.000247	0.000813	CcSEcCtD
Nilutamide—Dyspnoea—Mycophenolate mofetil—psoriasis	0.000246	0.000812	CcSEcCtD
Nilutamide—Decreased appetite—Cyclosporine—psoriasis	0.000246	0.000811	CcSEcCtD
Nilutamide—Depression—Methotrexate—psoriasis	0.000245	0.000806	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000245	0.000806	CcSEcCtD
Nilutamide—Ill-defined disorder—Dexamethasone—psoriasis	0.000245	0.000806	CcSEcCtD
Nilutamide—Ill-defined disorder—Betamethasone—psoriasis	0.000245	0.000806	CcSEcCtD
Nilutamide—Discomfort—Triamcinolone—psoriasis	0.000244	0.000805	CcSEcCtD
Nilutamide—Hyperhidrosis—Hydrocortisone—psoriasis	0.000243	0.000802	CcSEcCtD
Nilutamide—Dyspepsia—Mycophenolate mofetil—psoriasis	0.000243	0.000801	CcSEcCtD
Nilutamide—Constipation—Cyclosporine—psoriasis	0.000242	0.000798	CcSEcCtD
Nilutamide—Pain—Cyclosporine—psoriasis	0.000242	0.000798	CcSEcCtD
Nilutamide—Dry mouth—Triamcinolone—psoriasis	0.000242	0.000797	CcSEcCtD
Nilutamide—Decreased appetite—Mycophenolate mofetil—psoriasis	0.00024	0.000791	CcSEcCtD
Nilutamide—Anorexia—Hydrocortisone—psoriasis	0.00024	0.000791	CcSEcCtD
Nilutamide—Diarrhoea—Mycophenolic acid—psoriasis	0.00024	0.000789	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000239	0.000786	CcSEcCtD
Nilutamide—AR—Notch-mediated HES/HEY network—STAT3—psoriasis	0.000239	0.00554	CbGpPWpGaD
Nilutamide—Malaise—Dexamethasone—psoriasis	0.000238	0.000783	CcSEcCtD
Nilutamide—Malaise—Betamethasone—psoriasis	0.000238	0.000783	CcSEcCtD
Nilutamide—Oedema—Triamcinolone—psoriasis	0.000237	0.000781	CcSEcCtD
Nilutamide—Syncope—Dexamethasone—psoriasis	0.000236	0.000779	CcSEcCtD
Nilutamide—Syncope—Betamethasone—psoriasis	0.000236	0.000779	CcSEcCtD
Nilutamide—Pain—Mycophenolate mofetil—psoriasis	0.000236	0.000779	CcSEcCtD
Nilutamide—Constipation—Mycophenolate mofetil—psoriasis	0.000236	0.000779	CcSEcCtD
Nilutamide—Sweating—Methotrexate—psoriasis	0.000235	0.000775	CcSEcCtD
Nilutamide—Haematuria—Methotrexate—psoriasis	0.000234	0.000771	CcSEcCtD
Nilutamide—Feeling abnormal—Cyclosporine—psoriasis	0.000234	0.000769	CcSEcCtD
Nilutamide—Shock—Triamcinolone—psoriasis	0.000233	0.000768	CcSEcCtD
Nilutamide—Insomnia—Prednisolone—psoriasis	0.000233	0.000768	CcSEcCtD
Nilutamide—Alopecia—Prednisone—psoriasis	0.000233	0.000768	CcSEcCtD
Nilutamide—Gastrointestinal pain—Cyclosporine—psoriasis	0.000232	0.000763	CcSEcCtD
Nilutamide—Loss of consciousness—Dexamethasone—psoriasis	0.000232	0.000763	CcSEcCtD
Nilutamide—Loss of consciousness—Betamethasone—psoriasis	0.000232	0.000763	CcSEcCtD
Nilutamide—Dizziness—Mycophenolic acid—psoriasis	0.000232	0.000763	CcSEcCtD
Nilutamide—Paraesthesia—Prednisolone—psoriasis	0.000232	0.000763	CcSEcCtD
Nilutamide—AR—Gene Expression—TARS—psoriasis	0.000231	0.00537	CbGpPWpGaD
Nilutamide—Hyperhidrosis—Triamcinolone—psoriasis	0.000229	0.000755	CcSEcCtD
Nilutamide—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000228	0.00075	CcSEcCtD
Nilutamide—Insomnia—Hydrocortisone—psoriasis	0.000228	0.00075	CcSEcCtD
Nilutamide—Hypertension—Dexamethasone—psoriasis	0.000228	0.00075	CcSEcCtD
Nilutamide—Hypertension—Betamethasone—psoriasis	0.000228	0.00075	CcSEcCtD
Nilutamide—Paraesthesia—Hydrocortisone—psoriasis	0.000226	0.000745	CcSEcCtD
Nilutamide—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000226	0.000744	CcSEcCtD
Nilutamide—Abdominal pain—Cyclosporine—psoriasis	0.000224	0.000738	CcSEcCtD
Nilutamide—Body temperature increased—Cyclosporine—psoriasis	0.000224	0.000738	CcSEcCtD
Nilutamide—Vomiting—Mycophenolic acid—psoriasis	0.000223	0.000733	CcSEcCtD
Nilutamide—Discomfort—Dexamethasone—psoriasis	0.000222	0.00073	CcSEcCtD
Nilutamide—Discomfort—Betamethasone—psoriasis	0.000222	0.00073	CcSEcCtD
Nilutamide—Dyspepsia—Hydrocortisone—psoriasis	0.000222	0.00073	CcSEcCtD
Nilutamide—Rash—Mycophenolic acid—psoriasis	0.000221	0.000727	CcSEcCtD
Nilutamide—Dermatitis—Mycophenolic acid—psoriasis	0.000221	0.000727	CcSEcCtD
Nilutamide—Pain—Prednisolone—psoriasis	0.000221	0.000726	CcSEcCtD
Nilutamide—Headache—Mycophenolic acid—psoriasis	0.000219	0.000723	CcSEcCtD
Nilutamide—Decreased appetite—Hydrocortisone—psoriasis	0.000219	0.000721	CcSEcCtD
Nilutamide—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000219	0.00072	CcSEcCtD
Nilutamide—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000219	0.00072	CcSEcCtD
Nilutamide—Urinary tract disorder—Methotrexate—psoriasis	0.000218	0.000717	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000217	0.000716	CcSEcCtD
Nilutamide—Urethral disorder—Methotrexate—psoriasis	0.000216	0.000712	CcSEcCtD
Nilutamide—Pain—Hydrocortisone—psoriasis	0.000215	0.000709	CcSEcCtD
Nilutamide—Oedema—Dexamethasone—psoriasis	0.000215	0.000709	CcSEcCtD
Nilutamide—Oedema—Betamethasone—psoriasis	0.000215	0.000709	CcSEcCtD
Nilutamide—Insomnia—Triamcinolone—psoriasis	0.000214	0.000706	CcSEcCtD
Nilutamide—Ill-defined disorder—Prednisone—psoriasis	0.000213	0.000702	CcSEcCtD
Nilutamide—Paraesthesia—Triamcinolone—psoriasis	0.000213	0.000701	CcSEcCtD
Nilutamide—Feeling abnormal—Prednisolone—psoriasis	0.000212	0.0007	CcSEcCtD
Nilutamide—Visual impairment—Methotrexate—psoriasis	0.000212	0.0007	CcSEcCtD
Nilutamide—Anaemia—Prednisone—psoriasis	0.000212	0.000699	CcSEcCtD
Nilutamide—Shock—Dexamethasone—psoriasis	0.000212	0.000697	CcSEcCtD
Nilutamide—Shock—Betamethasone—psoriasis	0.000212	0.000697	CcSEcCtD
Nilutamide—Dyspnoea—Triamcinolone—psoriasis	0.000211	0.000696	CcSEcCtD
Nilutamide—Dyspepsia—Triamcinolone—psoriasis	0.000209	0.000687	CcSEcCtD
Nilutamide—Nausea—Mycophenolic acid—psoriasis	0.000208	0.000685	CcSEcCtD
Nilutamide—Hyperhidrosis—Dexamethasone—psoriasis	0.000208	0.000685	CcSEcCtD
Nilutamide—Hyperhidrosis—Betamethasone—psoriasis	0.000208	0.000685	CcSEcCtD
Nilutamide—AR—SIDS Susceptibility Pathways—IL10—psoriasis	0.000208	0.00482	CbGpPWpGaD
Nilutamide—Feeling abnormal—Hydrocortisone—psoriasis	0.000208	0.000683	CcSEcCtD
Nilutamide—Malaise—Prednisone—psoriasis	0.000207	0.000682	CcSEcCtD
Nilutamide—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000206	0.000678	CcSEcCtD
Nilutamide—Syncope—Prednisone—psoriasis	0.000206	0.000678	CcSEcCtD
Nilutamide—Anorexia—Dexamethasone—psoriasis	0.000205	0.000675	CcSEcCtD
Nilutamide—Anorexia—Betamethasone—psoriasis	0.000205	0.000675	CcSEcCtD
Nilutamide—Asthenia—Cyclosporine—psoriasis	0.000203	0.00067	CcSEcCtD
Nilutamide—Pain—Triamcinolone—psoriasis	0.000203	0.000668	CcSEcCtD
Nilutamide—Loss of consciousness—Prednisone—psoriasis	0.000202	0.000665	CcSEcCtD
Nilutamide—Pruritus—Cyclosporine—psoriasis	0.0002	0.00066	CcSEcCtD
Nilutamide—Abdominal pain—Hydrocortisone—psoriasis	0.000199	0.000656	CcSEcCtD
Nilutamide—Body temperature increased—Hydrocortisone—psoriasis	0.000199	0.000656	CcSEcCtD
Nilutamide—Asthenia—Mycophenolate mofetil—psoriasis	0.000198	0.000653	CcSEcCtD
Nilutamide—Hypertension—Prednisone—psoriasis	0.000198	0.000653	CcSEcCtD
Nilutamide—Pruritus—Mycophenolate mofetil—psoriasis	0.000196	0.000644	CcSEcCtD
Nilutamide—Feeling abnormal—Triamcinolone—psoriasis	0.000195	0.000644	CcSEcCtD
Nilutamide—Alopecia—Methotrexate—psoriasis	0.000195	0.000641	CcSEcCtD
Nilutamide—Insomnia—Dexamethasone—psoriasis	0.000195	0.000641	CcSEcCtD
Nilutamide—Insomnia—Betamethasone—psoriasis	0.000195	0.000641	CcSEcCtD
Nilutamide—Diarrhoea—Cyclosporine—psoriasis	0.000194	0.000639	CcSEcCtD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CXCL8—psoriasis	0.000194	0.0045	CbGpPWpGaD
Nilutamide—Paraesthesia—Dexamethasone—psoriasis	0.000193	0.000636	CcSEcCtD
Nilutamide—Paraesthesia—Betamethasone—psoriasis	0.000193	0.000636	CcSEcCtD
Nilutamide—Discomfort—Prednisone—psoriasis	0.000193	0.000636	CcSEcCtD
Nilutamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000192	0.00445	CbGpPWpGaD
Nilutamide—Dyspepsia—Dexamethasone—psoriasis	0.000189	0.000624	CcSEcCtD
Nilutamide—Dyspepsia—Betamethasone—psoriasis	0.000189	0.000624	CcSEcCtD
Nilutamide—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000189	0.000623	CcSEcCtD
Nilutamide—Body temperature increased—Triamcinolone—psoriasis	0.000187	0.000617	CcSEcCtD
Nilutamide—Dizziness—Cyclosporine—psoriasis	0.000187	0.000617	CcSEcCtD
Nilutamide—Oedema—Prednisone—psoriasis	0.000187	0.000617	CcSEcCtD
Nilutamide—Decreased appetite—Betamethasone—psoriasis	0.000187	0.000616	CcSEcCtD
Nilutamide—Decreased appetite—Dexamethasone—psoriasis	0.000187	0.000616	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Betamethasone—psoriasis	0.000186	0.000612	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000186	0.000612	CcSEcCtD
Nilutamide—Back pain—Methotrexate—psoriasis	0.000186	0.000611	CcSEcCtD
Nilutamide—Shock—Prednisone—psoriasis	0.000184	0.000607	CcSEcCtD
Nilutamide—Pain—Dexamethasone—psoriasis	0.000184	0.000606	CcSEcCtD
Nilutamide—Pain—Betamethasone—psoriasis	0.000184	0.000606	CcSEcCtD
Nilutamide—Dizziness—Mycophenolate mofetil—psoriasis	0.000183	0.000602	CcSEcCtD
Nilutamide—Hyperhidrosis—Prednisone—psoriasis	0.000181	0.000597	CcSEcCtD
Nilutamide—Asthenia—Hydrocortisone—psoriasis	0.000181	0.000595	CcSEcCtD
Nilutamide—Vomiting—Cyclosporine—psoriasis	0.00018	0.000593	CcSEcCtD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—JUN—psoriasis	0.00018	0.00418	CbGpPWpGaD
Nilutamide—Rash—Cyclosporine—psoriasis	0.000179	0.000588	CcSEcCtD
Nilutamide—Anorexia—Prednisone—psoriasis	0.000179	0.000588	CcSEcCtD
Nilutamide—Dermatitis—Cyclosporine—psoriasis	0.000179	0.000588	CcSEcCtD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—JUN—psoriasis	0.000178	0.00414	CbGpPWpGaD
Nilutamide—Pruritus—Hydrocortisone—psoriasis	0.000178	0.000587	CcSEcCtD
Nilutamide—Ill-defined disorder—Methotrexate—psoriasis	0.000178	0.000586	CcSEcCtD
Nilutamide—Headache—Cyclosporine—psoriasis	0.000178	0.000585	CcSEcCtD
Nilutamide—Anaemia—Methotrexate—psoriasis	0.000177	0.000584	CcSEcCtD
Nilutamide—Feeling abnormal—Betamethasone—psoriasis	0.000177	0.000584	CcSEcCtD
Nilutamide—Feeling abnormal—Dexamethasone—psoriasis	0.000177	0.000584	CcSEcCtD
Nilutamide—Gastrointestinal pain—Betamethasone—psoriasis	0.000176	0.000579	CcSEcCtD
Nilutamide—Gastrointestinal pain—Dexamethasone—psoriasis	0.000176	0.000579	CcSEcCtD
Nilutamide—Vomiting—Mycophenolate mofetil—psoriasis	0.000176	0.000579	CcSEcCtD
Nilutamide—Rash—Mycophenolate mofetil—psoriasis	0.000174	0.000574	CcSEcCtD
Nilutamide—Dermatitis—Mycophenolate mofetil—psoriasis	0.000174	0.000573	CcSEcCtD
Nilutamide—Headache—Mycophenolate mofetil—psoriasis	0.000173	0.00057	CcSEcCtD
Nilutamide—Malaise—Methotrexate—psoriasis	0.000173	0.00057	CcSEcCtD
Nilutamide—Diarrhoea—Hydrocortisone—psoriasis	0.000172	0.000567	CcSEcCtD
Nilutamide—Leukopenia—Methotrexate—psoriasis	0.000172	0.000566	CcSEcCtD
Nilutamide—Dizziness—Prednisolone—psoriasis	0.000171	0.000562	CcSEcCtD
Nilutamide—Asthenia—Triamcinolone—psoriasis	0.00017	0.00056	CcSEcCtD
Nilutamide—Abdominal pain—Betamethasone—psoriasis	0.00017	0.00056	CcSEcCtD
Nilutamide—Abdominal pain—Dexamethasone—psoriasis	0.00017	0.00056	CcSEcCtD
Nilutamide—Body temperature increased—Betamethasone—psoriasis	0.00017	0.00056	CcSEcCtD
Nilutamide—Body temperature increased—Dexamethasone—psoriasis	0.00017	0.00056	CcSEcCtD
Nilutamide—Insomnia—Prednisone—psoriasis	0.000169	0.000558	CcSEcCtD
Nilutamide—Nausea—Cyclosporine—psoriasis	0.000168	0.000554	CcSEcCtD
Nilutamide—Paraesthesia—Prednisone—psoriasis	0.000168	0.000554	CcSEcCtD
Nilutamide—Pruritus—Triamcinolone—psoriasis	0.000168	0.000553	CcSEcCtD
Nilutamide—Cough—Methotrexate—psoriasis	0.000167	0.000551	CcSEcCtD
Nilutamide—Dizziness—Hydrocortisone—psoriasis	0.000167	0.000548	CcSEcCtD
Nilutamide—AR—Androgen receptor signaling pathway—JUN—psoriasis	0.000165	0.00384	CbGpPWpGaD
Nilutamide—Dyspepsia—Prednisone—psoriasis	0.000165	0.000543	CcSEcCtD
Nilutamide—Nausea—Mycophenolate mofetil—psoriasis	0.000164	0.000541	CcSEcCtD
Nilutamide—Chest pain—Methotrexate—psoriasis	0.000163	0.000538	CcSEcCtD
Nilutamide—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	0.000163	0.00379	CbGpPWpGaD
Nilutamide—Decreased appetite—Prednisone—psoriasis	0.000163	0.000536	CcSEcCtD
Nilutamide—Rash—Prednisolone—psoriasis	0.000163	0.000535	CcSEcCtD
Nilutamide—Dermatitis—Prednisolone—psoriasis	0.000162	0.000535	CcSEcCtD
Nilutamide—Headache—Prednisolone—psoriasis	0.000162	0.000532	CcSEcCtD
Nilutamide—Discomfort—Methotrexate—psoriasis	0.000161	0.000532	CcSEcCtD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	0.000161	0.00374	CbGpPWpGaD
Nilutamide—Constipation—Prednisone—psoriasis	0.00016	0.000528	CcSEcCtD
Nilutamide—Vomiting—Hydrocortisone—psoriasis	0.00016	0.000527	CcSEcCtD
Nilutamide—Rash—Hydrocortisone—psoriasis	0.000159	0.000523	CcSEcCtD
Nilutamide—Dermatitis—Hydrocortisone—psoriasis	0.000159	0.000522	CcSEcCtD
Nilutamide—Headache—Hydrocortisone—psoriasis	0.000158	0.00052	CcSEcCtD
Nilutamide—Dizziness—Triamcinolone—psoriasis	0.000157	0.000516	CcSEcCtD
Nilutamide—Feeling abnormal—Prednisone—psoriasis	0.000154	0.000509	CcSEcCtD
Nilutamide—Asthenia—Dexamethasone—psoriasis	0.000154	0.000508	CcSEcCtD
Nilutamide—Asthenia—Betamethasone—psoriasis	0.000154	0.000508	CcSEcCtD
Nilutamide—Gastrointestinal pain—Prednisone—psoriasis	0.000153	0.000505	CcSEcCtD
Nilutamide—Nausea—Prednisolone—psoriasis	0.000153	0.000504	CcSEcCtD
Nilutamide—Pruritus—Betamethasone—psoriasis	0.000152	0.000501	CcSEcCtD
Nilutamide—Pruritus—Dexamethasone—psoriasis	0.000152	0.000501	CcSEcCtD
Nilutamide—Hyperhidrosis—Methotrexate—psoriasis	0.000151	0.000499	CcSEcCtD
Nilutamide—AR—Generic Transcription Pathway—CARM1—psoriasis	0.000151	0.00351	CbGpPWpGaD
Nilutamide—Vomiting—Triamcinolone—psoriasis	0.000151	0.000497	CcSEcCtD
Nilutamide—Nausea—Hydrocortisone—psoriasis	0.00015	0.000493	CcSEcCtD
Nilutamide—Rash—Triamcinolone—psoriasis	0.00015	0.000492	CcSEcCtD
Nilutamide—Dermatitis—Triamcinolone—psoriasis	0.000149	0.000492	CcSEcCtD
Nilutamide—Anorexia—Methotrexate—psoriasis	0.000149	0.000492	CcSEcCtD
Nilutamide—Headache—Triamcinolone—psoriasis	0.000149	0.000489	CcSEcCtD
Nilutamide—Body temperature increased—Prednisone—psoriasis	0.000148	0.000488	CcSEcCtD
Nilutamide—Abdominal pain—Prednisone—psoriasis	0.000148	0.000488	CcSEcCtD
Nilutamide—Diarrhoea—Betamethasone—psoriasis	0.000147	0.000485	CcSEcCtD
Nilutamide—Diarrhoea—Dexamethasone—psoriasis	0.000147	0.000485	CcSEcCtD
Nilutamide—AR—Androgen receptor signaling pathway—STAT3—psoriasis	0.000143	0.00332	CbGpPWpGaD
Nilutamide—Dizziness—Betamethasone—psoriasis	0.000142	0.000469	CcSEcCtD
Nilutamide—Dizziness—Dexamethasone—psoriasis	0.000142	0.000469	CcSEcCtD
Nilutamide—Insomnia—Methotrexate—psoriasis	0.000142	0.000466	CcSEcCtD
Nilutamide—Nausea—Triamcinolone—psoriasis	0.000141	0.000464	CcSEcCtD
Nilutamide—Paraesthesia—Methotrexate—psoriasis	0.000141	0.000463	CcSEcCtD
Nilutamide—Dyspnoea—Methotrexate—psoriasis	0.00014	0.00046	CcSEcCtD
Nilutamide—Dyspepsia—Methotrexate—psoriasis	0.000138	0.000454	CcSEcCtD
Nilutamide—Vomiting—Betamethasone—psoriasis	0.000137	0.000451	CcSEcCtD
Nilutamide—Vomiting—Dexamethasone—psoriasis	0.000137	0.000451	CcSEcCtD
Nilutamide—Decreased appetite—Methotrexate—psoriasis	0.000136	0.000448	CcSEcCtD
Nilutamide—Rash—Dexamethasone—psoriasis	0.000136	0.000447	CcSEcCtD
Nilutamide—Rash—Betamethasone—psoriasis	0.000136	0.000447	CcSEcCtD
Nilutamide—Dermatitis—Betamethasone—psoriasis	0.000136	0.000446	CcSEcCtD
Nilutamide—Dermatitis—Dexamethasone—psoriasis	0.000136	0.000446	CcSEcCtD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	0.000135	0.00314	CbGpPWpGaD
Nilutamide—Gastrointestinal disorder—Methotrexate—psoriasis	0.000135	0.000445	CcSEcCtD
Nilutamide—Headache—Betamethasone—psoriasis	0.000135	0.000444	CcSEcCtD
Nilutamide—Headache—Dexamethasone—psoriasis	0.000135	0.000444	CcSEcCtD
Nilutamide—Asthenia—Prednisone—psoriasis	0.000134	0.000443	CcSEcCtD
Nilutamide—Pain—Methotrexate—psoriasis	0.000134	0.000441	CcSEcCtD
Nilutamide—Pruritus—Prednisone—psoriasis	0.000133	0.000437	CcSEcCtD
Nilutamide—Feeling abnormal—Methotrexate—psoriasis	0.000129	0.000425	CcSEcCtD
Nilutamide—Diarrhoea—Prednisone—psoriasis	0.000128	0.000422	CcSEcCtD
Nilutamide—Gastrointestinal pain—Methotrexate—psoriasis	0.000128	0.000422	CcSEcCtD
Nilutamide—Nausea—Dexamethasone—psoriasis	0.000128	0.000421	CcSEcCtD
Nilutamide—Nausea—Betamethasone—psoriasis	0.000128	0.000421	CcSEcCtD
Nilutamide—Dizziness—Prednisone—psoriasis	0.000124	0.000408	CcSEcCtD
Nilutamide—Abdominal pain—Methotrexate—psoriasis	0.000124	0.000408	CcSEcCtD
Nilutamide—Body temperature increased—Methotrexate—psoriasis	0.000124	0.000408	CcSEcCtD
Nilutamide—Vomiting—Prednisone—psoriasis	0.000119	0.000392	CcSEcCtD
Nilutamide—Rash—Prednisone—psoriasis	0.000118	0.000389	CcSEcCtD
Nilutamide—Dermatitis—Prednisone—psoriasis	0.000118	0.000389	CcSEcCtD
Nilutamide—Headache—Prednisone—psoriasis	0.000117	0.000387	CcSEcCtD
Nilutamide—AR—SIDS Susceptibility Pathways—CXCL8—psoriasis	0.000114	0.00264	CbGpPWpGaD
Nilutamide—Asthenia—Methotrexate—psoriasis	0.000112	0.00037	CcSEcCtD
Nilutamide—Nausea—Prednisone—psoriasis	0.000111	0.000367	CcSEcCtD
Nilutamide—Pruritus—Methotrexate—psoriasis	0.000111	0.000365	CcSEcCtD
Nilutamide—AR—Integrated Breast Cancer Pathway—JUN—psoriasis	0.000108	0.00252	CbGpPWpGaD
Nilutamide—Diarrhoea—Methotrexate—psoriasis	0.000107	0.000353	CcSEcCtD
Nilutamide—AR—SIDS Susceptibility Pathways—JUN—psoriasis	0.000106	0.00245	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—NFKB1—psoriasis	0.000104	0.00242	CbGpPWpGaD
Nilutamide—Dizziness—Methotrexate—psoriasis	0.000104	0.000341	CcSEcCtD
Nilutamide—AR—SIDS Susceptibility Pathways—NFKB1—psoriasis	0.000102	0.00236	CbGpPWpGaD
Nilutamide—Vomiting—Methotrexate—psoriasis	9.96e-05	0.000328	CcSEcCtD
Nilutamide—Rash—Methotrexate—psoriasis	9.87e-05	0.000325	CcSEcCtD
Nilutamide—Dermatitis—Methotrexate—psoriasis	9.86e-05	0.000325	CcSEcCtD
Nilutamide—Headache—Methotrexate—psoriasis	9.81e-05	0.000323	CcSEcCtD
Nilutamide—AR—Integrated Breast Cancer Pathway—VEGFA—psoriasis	9.47e-05	0.0022	CbGpPWpGaD
Nilutamide—Nausea—Methotrexate—psoriasis	9.3e-05	0.000306	CcSEcCtD
Nilutamide—AR—SIDS Susceptibility Pathways—VEGFA—psoriasis	9.23e-05	0.00214	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—VDR—psoriasis	9.02e-05	0.00209	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	8.98e-05	0.00208	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	8.65e-05	0.00201	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—TNF—psoriasis	7.91e-05	0.00184	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	7.85e-05	0.00182	CbGpPWpGaD
Nilutamide—AR—Gene Expression—CARM1—psoriasis	7.28e-05	0.00169	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—TP53—psoriasis	7.15e-05	0.00166	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	6.72e-05	0.00156	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—IL6—psoriasis	6.38e-05	0.00148	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—NDUFA5—psoriasis	6.37e-05	0.00148	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—PPARG—psoriasis	6.29e-05	0.00146	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	5.94e-05	0.00138	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	5.93e-05	0.00138	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—NDUFA5—psoriasis	5.69e-05	0.00132	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—CYP2S1—psoriasis	5.42e-05	0.00126	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	5.3e-05	0.00123	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—NDUFA5—psoriasis	5.19e-05	0.0012	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—CYP2S1—psoriasis	4.84e-05	0.00112	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.84e-05	0.00112	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—CYP2S1—psoriasis	4.41e-05	0.00102	CbGpPWpGaD
Nilutamide—AR—Gene Expression—VDR—psoriasis	4.34e-05	0.00101	CbGpPWpGaD
Nilutamide—AR—Gene Expression—PPARG—psoriasis	3.03e-05	0.000703	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.84e-05	0.000659	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—CARM1—psoriasis	2.65e-05	0.000614	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.53e-05	0.000588	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.47e-05	0.000574	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—CARM1—psoriasis	2.36e-05	0.000548	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.31e-05	0.000536	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.21e-05	0.000512	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—CARM1—psoriasis	2.15e-05	0.0005	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.01e-05	0.000467	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—CAT—psoriasis	1.63e-05	0.000378	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—CAT—psoriasis	1.45e-05	0.000337	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—CAT—psoriasis	1.32e-05	0.000307	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—APOE—psoriasis	1.26e-05	0.000294	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—APOE—psoriasis	1.13e-05	0.000262	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PPARG—psoriasis	1.1e-05	0.000256	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—APOE—psoriasis	1.03e-05	0.000239	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PPARG—psoriasis	9.83e-06	0.000228	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PPARG—psoriasis	8.97e-06	0.000208	CbGpPWpGaD
